<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01164202</url>
  </required_header>
  <id_info>
    <org_study_id>PRODIGE 16</org_study_id>
    <secondary_id>FFCD-PRODIGE-16</secondary_id>
    <secondary_id>FFCD-0905</secondary_id>
    <secondary_id>EUDRACT-2009-017064-16</secondary_id>
    <secondary_id>EU-21050</secondary_id>
    <nct_id>NCT01164202</nct_id>
  </id_info>
  <brief_title>Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer</brief_title>
  <acronym>SATURNE</acronym>
  <official_title>A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoembolization kills tumor cells by blocking the blood flow to the tumor and&#xD;
      keeping anticancer drugs near the tumor. Sunitinib malate may stop the growth of tumor cells&#xD;
      by blocking some of the enzymes needed for cell growth and by blocking blood flow to the&#xD;
      tumor. It is not yet known whether chemoembolization is more effective with or without&#xD;
      sunitinib malate in treating patients with liver cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase II/III trial is studying the side effects of chemoembolization&#xD;
      of the liver and to see how well in works when given together with or without sunitinib&#xD;
      malate in treating patients with liver cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate unacceptable bleeding or hepatic failure at 10 weeks post-treatment in&#xD;
           patients with unresectable hepatocellular carcinoma treated with transarterial&#xD;
           chemoembolization in combination with sunitinib malate versus transarterial&#xD;
           chemoembolization alone.&#xD;
&#xD;
        -  To evaluate the overall survival of these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To evaluate the tumor stabilization rate in these patients.&#xD;
&#xD;
        -  To evaluate the safety of this regimen in these patients.&#xD;
&#xD;
        -  To evaluate the disease-free survival of these patients.&#xD;
&#xD;
        -  To evaluate the relapse-free survival of these patients.&#xD;
&#xD;
        -  To evaluate the quality of life of these patients.&#xD;
&#xD;
        -  To evaluate the overall survival rate at 2 years of these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Pilot: Patients receive oral sunitinib malate once daily on days 1-28. Beginning 7-10 days&#xD;
      later, patients undergo 1-3 courses of transarterial chemoembolization (TACE). Treatment&#xD;
      repeats every 6 weeks for 1 year.&#xD;
&#xD;
      Randomization: Patients are stratified according to main tumor diameter (&lt; 5 cm vs ≥ 5 cm),&#xD;
      nodular involvement (uninodular vs multinodular), and center. Patients are randomized to 1 of&#xD;
      2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive sunitinib malate and TACE as in the pilot phase.&#xD;
&#xD;
        -  Arm II: Patients receive oral placebo once daily on days 1-28 and TACE as in the pilot&#xD;
           phase.&#xD;
&#xD;
      Quality of life is assessed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of severe bleeding or liver failure</measure>
    <time_frame>during the week following each TACE</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicities</measure>
    <time_frame>From Inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From Inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo 3cps/days 4 weeks over 6 during 1 year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sunitinib malate</intervention_name>
    <description>placebo 3cps/days 4 weeks over 6 during 1 year</description>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 3cps/days 4 weeks over 6 during 1 year</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>transarterial chemoembolization</intervention_name>
    <description>Chimioembolisation</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sunitinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma or liver tumor responding to the&#xD;
             Barcelona criteria&#xD;
&#xD;
          -  Child-Pugh score of 5-6 (Class A)&#xD;
&#xD;
          -  Tumor suitable for transarterial chemoembolization (one or more planned courses&#xD;
             allowed)&#xD;
&#xD;
          -  Tumor not suitable for surgical resection&#xD;
&#xD;
          -  No extrahepatic metastases, including cerebral metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
          -  Platelet count ≥ 100 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  PT ≥ 50%&#xD;
&#xD;
          -  Creatinine ≤ 120 μmol/L&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT/AST ≤ 3.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatases ≤ 4 times ULN&#xD;
&#xD;
          -  Fibrinogen ≥ 1.5 g/L&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No portal vein thrombosis&#xD;
&#xD;
          -  Able to comply with scheduled follow-up and management of toxicity&#xD;
&#xD;
          -  No uncontrolled hypertension or requiring ≥ 2 classes of antihypertensive drugs&#xD;
&#xD;
          -  No concomitant disease or uncontrolled severe disease&#xD;
&#xD;
          -  No contraindications to the vascular occlusion procedure&#xD;
&#xD;
          -  No prior or concurrent malignancy within the past 5 years, except adequately treated&#xD;
             cone-biopsied carcinoma in situ of the cervix or basal cell carcinoma of the skin&#xD;
&#xD;
          -  No psychiatric disability or social, family, or geographic reason for which the&#xD;
             patient may not be followed regularly&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  At least 7 days since prior CYP3A4 inhibitors or inducers&#xD;
&#xD;
          -  At least 3 months since prior radiofrequency ablation&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior sunitinib, sorafenib, or any other inhibitors of angiogenesis&#xD;
&#xD;
          -  No concurrent participation in another trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed Hebbar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospital Universitaire Hop Huriez</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nord</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU J Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Béziers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique des Cèdres</name>
      <address>
        <city>Cornebarrieu</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Guilherand Granges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHBS</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Ambroise Paré</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Conception</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU -Hôpital de l'Archet II</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75970</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Paris St Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Jean Bernard</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAC</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Turpin A, de Baere T, Heurgué A, Le Malicot K, Ollivier-Hourmand I, Lecomte T, Perrier H, Vergniol J, Sefrioui D, Rinaldi Y, Edeline J, Jouve JL, Silvain C, Becouarn Y, Dauvois B, Baconnier M, Debette-Gratien M, Deplanque G, Dharancy S, Lepage C, Hebbar M; PRODIGE 16 investigators Collaborators. Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. Clin Res Hepatol Gastroenterol. 2021 Mar;45(2):101464. doi: 10.1016/j.clinre.2020.05.012. Epub 2020 Jun 21.</citation>
    <PMID>32576496</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2010</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 23, 2021</submitted>
    <returned>September 17, 2021</returned>
    <submitted>October 20, 2021</submitted>
    <returned>November 17, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

